Abstract
Background: Depression is a chronic relapsing and recurring disorder. Relapse rate are about 50% in people with depression previously treated adequately by the antidepressant. Our study aims to compare the relapse rates in patients treated with Escitalopram, a selective serotonin reuptake inhibitor (SSRI) and milnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI).
Method: Our study aims to compare the relapse rate after Escitalopram and Milnacipran continuation treatment. Out patients of Psychiatry diagnosed with depression were assigned to receive acute phase treatment with either Escitalopram or Milnacipran for a duration of 8week.Remmiters in both the group then received continuation treatment with the same drugs for a period of 20weeks .Then the patients were followed up for a total of 12 months from the start of therapy. The relapse rate in both the group were compared.
Conclusion: Relapse rates among patients in both the groups were found to be comparable in our study
Keywords- SSRI, SNRI, Escitalopram, Milnacipran, relapse, remission.
References
- Angst J. Course of mood disorders: A challenge to psychopharmacology. Clin Neuropharmacol. 1992;15(Suppl 1 Pt A):444–445.
- . Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: A prospective study. Am J Psychiatry. 1992;149(6):795–800
- ThomasCM,,Morris S(2003).Cost of depression among adults in England in 2000Br J Psychiatry183:514–
- BauerM, Severus E,Köhler S, Whybrow PC, Angst J, Möller HJ(2015). World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Unipolar Depressive Disorders. Guidelines for biological treatment of unipolar depressive disorders. World J Biol Psychiatry 16: 76–
- Segal, Z., Pearson, J. & Thase, M. E. (2003)Challenges in preventing relapse in major depression.Report of a National Institute of Mental Health Workshop on state of the science of . relapse prevention in major depression. Journal of Affective Disorders, 77,97-108.
- American Psychiatric Association. Practice Guideline for the Treatment of patients with major depressive disorder(Revision).Am J Psychiatry 2000;157(suppl 4):1-45
- Geddes JR, Carney SM, Davies C, et al. Relapse prevention with anti-depressant drug treatment in depressive disorders: a systematic review.
- Melfi,C. A.,Chawla, A. J.,Croghan,T.W., et al (1998) The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depresssion. Archives of General Psychiatry, 55,1128-1132.
- Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Archives of General Psychiatry. 1991;48: 851–855.
- Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF: Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006; 31:1841–1853 [G]
- Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB: Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50:97–108
- Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, Mueller T, Solomon DA, Keller MB: Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157:1501–1504.
- Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J.Clin. Psychiatry 65, 44-49 (2004)
- Gorwood P, Weiller E, Lemming O,Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. J. Geriatr. Psychiatry. 15(7), 581–593 (2007)
- Kornstein SG, Bose A, Li D, Saikali KG,Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo controlled trial. Clin. Psychiatry 67, 1767–1775 (2006).
- David g., Inmaculada gilaberte, Fujun wang. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. British journal of psychiatry (2 0 0 6), 1 8 8 , 3 4 6 - 3 5 3).
- Rouillon F, Warner B, Pezous N, et al. Milnacipran efficacy in the prevention of recurrent depression: A 12-month placebo-controlled study. Int Clin Psychopharmacol. 2000;15(3):133–140).
Corresponding Author
Dr Pankaj Shinde
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v6i3.219
